PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-62.27%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
43.14%
G&A change of 43.14% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.75%
Operating expenses reduction while Biotechnology median is 7.15%. Seth Klarman would investigate advantages.
-7.75%
Total costs reduction while Biotechnology median is 6.39%. Seth Klarman would investigate advantages.
-100.00%
Interest expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
975.86%
D&A change of 975.86% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
-265.35%
EBITDA decline while Biotechnology median is -1.43%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
7.75%
Operating income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
-2437.42%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-313.81%
Pre-tax income decline while Biotechnology median is -4.50%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-313.81%
Net income decline while Biotechnology median is -4.26%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-286.19%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-286.19%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
6.89%
Share count change of 6.89% versus stable Biotechnology. Walter Schloss would verify approach.
6.89%
Diluted share change of 6.89% versus stable Biotechnology. Walter Schloss would verify approach.